Method and intermediate for preparing oxetane-2-ylmethylamine
By introducing protected nitrogen in the preparation of oxetane-2-ylmethylamine and reacting with trimethyl sulfoxide and alkali metal, the toxicity and safety risks of azide compounds were solved, and the problem of More efficient and safer production process.
Patent Information
- Application Number
- CN202080082957.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-10
- Filing Date
- 2020-12-07
- Publication Date
- 2024-12-24
- Estimated Expiration
- 2040-12-07
AI Technical Summary
The use of azide compounds in the existing methods for preparing oxetane-2-ylmethylamine is highly toxic and physically dangerous, and requires a large number of expensive safety measures, high resource intensiveness, and complex steps, requiring a A safer and more efficient way.
Protected nitrogen is introduced before the ring expansion step, protecting nitrogen by two benzyls, reacting with trimethyl sulfoxide and alkali metal to produce oxetane-2-ylmethylamine, avoiding the use of azides, simplifying Steps and reduce security risks.
A safer and more resource-efficient preparation of oxetane-2-ylmethylamine is achieved, reducing the demand for operating steps and safety measures and reducing production costs.
Smart Images

Figure CN114728923B_ABST
Abstract
Description
[0001] The present invention relates to a method and intermediates for preparing oxetane-2-ylmethylamine, which is a key intermediate in the preparation of certain glucagon-like peptide-1 receptor agonists.
[0002] Oxetane-2-ylmethylamine is a key intermediate in the preparation of certain glucagon-like peptide-1 receptor agonists, including certain 1-[2-oxetane-2-ylmethyl]-1H-benzimidazole compounds disclosed in WO2018 / 109607. The method for preparing (S)-oxetane-2-ylmethylamine disclosed in WO2018 / 109607 is a five-step method starting with (S)-2-((benzyloxy)methyl)oxirane. The first step is a ring expansion step, which expands oxirane to oxetane. In the penultimate step, sodium azide is used to introduce the nitrogen of the amine group, and in the last step, the azide intermediate is reduced to provide the amine group. Azide compounds are highly toxic. Certain azide compounds also present significant physical hazards because they are sensitive to heat and shock and can explosively decompose with only a small amount of external energy input. Therefore, the last two steps of this approach carry significant responsibility and require extensive and expensive safety measures.
[0003] Improved methods that are less resource intensive, less expensive, and / or facilitate more efficient production are needed. Methods that avoid the use of toxic and hazardous azide-based compounds are particularly needed. In addition, simpler methods that require fewer operations are needed.
[0004] The process of the present invention addresses these requirements by introducing a protected nitrogen prior to the ring expansion step. The nitrogen is protected by two benzyl groups.
[0005] Accordingly, in one embodiment, the present invention provides a method for preparing a compound of the following formula or a salt thereof:
[0006]
[0007] It includes the following steps:
[0008] i. Combine dibenzylamine and a compound of the formula:
[0009]
[0010] A base is then added to produce a compound of the formula:
[0011]
[0012] ii. Take trimethylsulfuxonium halide in the presence of a base and combine with the solution of the compound obtained from step (i) and heat to above 40°C to produce a compound of the formula:
[0013]
[0014] iii. deprotecting the compound obtained in step (ii).
[0015] In one embodiment, the compound of Formula I is:
[0016]
[0017] or a salt thereof. This formula represents the S-enantiomer.
[0018] In one embodiment, the compound of formula I is the hydrochloride salt of the compound of the formula:
[0019] .
[0020] In one embodiment, the trimethylsulfuxonium halide is trimethylsulfuxonium iodide.
[0021] In one embodiment, the base in step (ii) is a base different from the base used in step (i). In one embodiment, the base in step (ii) is selected from alkali metal hydrides, hindered alkali metal alkoxides, alkyl lithiums in hindered alcohol solvents, alkali metal hexamethyldisilylazane. In a specific embodiment, the base in step (ii) is selected from potassium tert-butoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-amyl alkoxide, lithium tert-amyl alkoxide, sodium tert-amyl alkoxide, lithium potassium hydride, sodium hydride, potassium hydride, n-butyl lithium in alcohol solvents, lithium hexamethyldisilazide, sodium hexamethyldisilazide or potassium hexamethyldisilazide. In a preferred embodiment, the base is potassium tert-butoxide.
[0022] In one embodiment, the solution in step (ii) comprises a solvent selected from a polar aprotic solvent or a hindered alcohol. In a particular embodiment, the solvent is selected from: tert-butyl alcohol, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or tert-amyl alcohol. In a preferred embodiment, the solvent is tert-butyl alcohol.
[0023] In one embodiment, step (ii) is carried out at a temperature above 70°C. In a preferred embodiment, step (ii) is carried out at a temperature above 80°C. In another preferred embodiment, step (ii) is carried out at a temperature of 80-90°C. In another preferred embodiment, step (ii) is carried out at a temperature of 80-85°C.
[0024] In one embodiment, step (iii) is carried out using a palladium catalyst. In a preferred embodiment, the palladium catalyst is palladium on carbon.
[0025] The method may further comprise the following steps (herein referred to as step (iv)):
[0026] A base and a compound of the formula:
[0027]
[0028] Wherein R is H or an acid protecting group,
[0029] Combined with a solution of a compound of the formula:
[0030]
[0031] To produce the following compound:
[0032] .
[0033] In one embodiment of step (iv), R in the compounds of formula V and VI is H or C 1-4 In one embodiment, R is H. In another embodiment, R is C 1-4 Alkyl group, preferably methyl group.
[0034] In one embodiment, R is H and step (iv) comprises combining a base and 3-fluoro-4-nitrobenzoic acid with a solution of a compound of the formula:
[0035]
[0036] To produce the following compound:
[0037] .
[0038] In one embodiment, R is methyl and step (iv) comprises adding a base and methyl 3-fluoro-4-nitrobenzoate to a solution of a compound of the formula:
[0039]
[0040] To produce the following compound:
[0041] .
[0042] Continuing from step (iv), the method may further comprise the following steps (herein referred to as step (v)):
[0043] Reduction of the nitro group of the compound of the formula:
[0044]
[0045] To produce the following compound:
[0046] .
[0047] In one embodiment of step (v), R in the compounds of formula VI and VII is H. In another embodiment of step (v), R in the compounds of formula VI and VII is C 1-4 Alkyl group, preferably methyl group.
[0048] Continuing from step (v), the method may further comprise the following steps:
[0049] vi. to carry out the compound of the following formula:
[0050]
[0051] With the amide coupling reaction of the compound of the following formula:
[0052]
[0053] To produce the following compound:
[0054]
[0055] or its salts;
[0056] vii. subjecting the compound obtained in step (vi) to a cyclization reaction to produce a compound of the formula:
[0057]
[0058] and optionally reacting to form a pharmaceutically acceptable salt thereof.
[0059] In one embodiment of steps (vi) and (vii), R in the compounds of formula VII, IX and X is H. In another embodiment of steps (vi) and (vii), R in the compounds of formula VII, IX and X is C 1-4 Alkyl group, preferably methyl group.
[0060] In one embodiment, R in the compounds of formula VI, VII, IX and X is an acid protecting group, and the method further comprises the following step (herein step (viii)): hydrolyzing the ester group to produce an acid compound of formula X wherein R is H:
[0061]
[0062] and optionally reacting to form a pharmaceutically acceptable salt thereof.
[0063] In one embodiment, the compound formed in step (vii) or step (viii) is the tert-butylamine salt of the compound of the formula:
[0064] .
[0065] Preferably, the compound is the tert-butylamine salt of the compound of the formula:
[0066] .
[0067] In one embodiment, a compound of the formula is provided:
[0068]
[0069] or a salt thereof.
[0070] In a preferred embodiment, the compound is a compound of the formula:
[0071]
[0072] or a salt thereof. This formula represents the S-enantiomer.
[0073] Further provided herein are compounds of the formula:
[0074]
[0075] Use in the preparation of a compound of the following formula or a pharmaceutically acceptable salt thereof:
[0076] .
[0077] The formation of the epoxide in step (i) is known, for example, Scheme 1 of Synthetic Communications, 45:2576-2582, 2015 and Example 1 in WO 2012 / 153155. The skilled person will recognize that various bases and solvents can be used in this step. Suitable solvents include hindered alcohols, particularly 2-propanol. There are many suitable bases, including sodium hydroxide, potassium hydroxide and lithium hydroxide. This step can be carried out by adding epichlorohydrin to dibenzylamine and 2-propanol at low temperature, preferably below 5°C. The reaction mixture can then be heated to ambient temperature, preferably to 20-25°C, and stirred. The solution can then be cooled to below 5°C, then a base is added, and then heated to ambient temperature, preferably about 20°C. Alternatively, the addition of epichlorohydrin to dibenzylamine and 2-propanol can be carried out at a temperature of 10-20°C, then a base is added and stirred at 20-25°C.
[0078] The deprotection step (step (iii)) can be carried out by a number of different methods known in the art, "Protective groups in organic synthesis", TW Greene and PGM Wuts, Wiley, 3 rd Ed, 1999, Hoboken, NJ, pp. 579-580. For example, a palladium catalyst can be used. If the compound of formula I is a hydrochloride, preferably 0.8 to 1 molar equivalent of hydrochloric acid is used, preferably about 0.9 molar equivalent. Many solvents can be used in this step, including, for example, ethanol or methanol. In one embodiment, the compound obtained from step (ii) is continued in solution, for example, in an ethanol solution, for step (iii).
[0079] Optional step (iv) can be carried out using methods taught in the art, see, for example, the preparation method of intermediate 24 in WO 2018 / 109607. In one embodiment of step (iv), oxetane-2-ylmethylamine or its salt is dissolved in dimethylformamide. In another embodiment, oxetane-2-ylmethylamine can be used in, for example, a lower alkyl alcohol solution, particularly an ethanol solution. This solution can come directly from the previous step (iii).
[0080] In another embodiment of step (iv), this step is performed at ambient temperature. In another embodiment, this step is performed at a temperature of 110-120°C.
[0081] A preferred base in step (iv) is triethylamine.
[0082] Methods for carrying out the reduction of the nitro group to form an amine in step (v) are well known in the art. For example, it can be carried out using a palladium catalyst, such as palladium on carbon.
[0083] The amide coupling reaction in step (vi) can be carried out using methods known in the art. In one embodiment, the coupling can be carried out using 1,1-carbonyldiimidazole. Preferably, 1,1-carbonyldiimidazole is first added to 2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-fluoro-5-methylphenyl)acetic acid in a solvent such as tetrahydrofuran, and sufficient time is allowed to form the reactive intermediate before adding the compound of formula VII. Alternatively, the amide coupling step can use other coupling conditions, such as using HATU (1-[bis(dimethylamino)methylene]-1 H -1,2,3-triazolo[4,5- b ]pyridinium 3-oxide hexafluorophosphate).
[0084] The cyclization reaction in step (vii) can be carried out by heating, for example, to above 80° C., optionally in the presence of an acid.
[0085] As described above, when R in the compounds of formula VI, VII, IX and X in steps (iv), (v), (vi) and (vii) is an acid protecting group, the method may further include a step of hydrolyzing the ester compound to provide the final acid compound (formula X') (step (viii)). This step can be carried out, for example, by heating the ester in the presence of a base such as lithium hydroxide.
[0086] In a particular embodiment, R in the compounds of formula VI, VII, IX and X in steps (iv), (v), (vi) and (vii) is H, and the final step (viii) is not required. This is advantageous because it reduces the number of synthetic steps. In addition, if this hydrolysis step is carried out by heating the ester in the presence of a base, this step may lead to undesirable side reactions at the nitrile group.
[0087] Steps (iv), (v), (vi) and (vii) all involve a compound having an R group. At each occurrence, R is H or an acid protecting group. As the skilled artisan will recognize, the R group remains the same in each of these successive steps. In one embodiment, R is H. In another embodiment, R is C 1-4 In step (viii), the compound of formula X wherein R is an acid protecting group is hydrolyzed to a compound of formula X wherein R is H (formula X').
[0088] The compounds of Formula I, II, III, IV, VI, VII, IX and X all have a chiral center at the point of attachment of the oxirane or oxetane. Although the process steps include the use of all individual enantiomers and mixtures thereof as well as racemates, certain configurations are preferred:
[0089]
[0090]
[0091] .
[0092] Formulas Ia, IVa, VIa, VIIa, IXa and Xa represent the S-enantiomer. Formulas IIb and IIIb represent the R-enantiomer.
[0093] The term "pharmaceutically acceptable salt" as used herein refers to salts of compounds that are considered acceptable for clinical and / or veterinary use. Examples of pharmaceutically acceptable salts and common methods for preparing them can be found in "Handbook of Pharmaceutical Salts: Properties, Selection and Use" P. Stahl et al., Second Revised Edition, Wiley-VCH, 2011 and SM Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, 1977, 66(1), 1-19. The preferred salt of the compound of formula X is the tert-butylamine (or erbumine) salt.
[0094] R in the compounds of Formula V, VI, VII, IX and X described herein may be an acid protecting group. It is to be understood that, as will be appreciated by those skilled in the art, the protecting group may vary depending on the particular reaction conditions and the particular transformation to be performed. Acid protecting groups and protection and deprotection conditions are well known to the skilled artisan and are described in the literature (see, e.g., " Greene's Protective Groups in Organic Synthesis ”, 4th ed., Peter GM Wuts and Theodora W. Greene, John Wiley and Sons, Inc. 2007).
[0095] Certain abbreviations are defined as follows: “ACN” refers to acetonitrile; “DCM” refers to dichloromethane; “DMEA” refers to N,N-dimethylethylamine; “DMF” refers to N,N-dimethylformamide; “DMSO” refers to dimethyl sulfoxide; “ES-MS” refers to electrospray mass spectrometry; “EtOAc” refers to ethyl acetate; “EtOH” refers to ethanol or ethyl alcohol; “h” refers to hour; “HPLC” refers to high performance liquid chromatography; “MeOH” refers to methanol or methyl alcohol; “MTBE” refers to methyl tert-butyl ether; “min” refers to minute; “m / z” refers to mass-to-charge ratio; “Pd(dppf)Cl2” refers to [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II); “RT” refers to room temperature; “TFA” refers to trifluoroacetic acid; and “THF” refers to tetrahydrofuran.
[0096] The X-ray powder diffraction (XRPD) pattern of the crystalline solid was obtained on a Bruker D4 Endeavor X-ray powder diffractometer equipped with a CuKα source and a Vantec detector, operating at 35 kV and 50 mA. The sample was scanned at a step size of 0.008 2θ° and a scan rate of 0.5 seconds / step from 4 to 40 2θ°, and a 1.0 mm divergence slit, a 6.6 fixed anti-scattering slit, and an 11.3 mm detector slit were used. The dry powder was mounted on a quartz sample holder and a glass slide was used to obtain a smooth surface. The crystal diffraction pattern was collected at ambient temperature and relative humidity. Based on the NIST 675 internal standard with peaks at 8.853 and 26.774 2θ°, the crystal peak position was determined in MDI-Jade after the full pattern shift. It is well known in the field of crystallography that for any given crystal form, the relative intensity of the diffraction peaks can be variable due to the preferred orientation caused by factors such as crystal morphology and habit. If there is a preferred orientation effect, the peak intensity changes, but the characteristic peak position of the polymorph remains unchanged. See, for example, The United States Pharmacopeia #23, National Formulary #18, pp. 1843-1844, 1995. In addition, it is also well known in the field of crystallography that for any given crystal form, the angular peak position may change slightly. For example, the peak position may move due to temperature changes, sample displacement, or the presence or absence of an internal standard when analyzing the sample. In this case, a peak position variability of ± 0.2 2θ° is assumed to take into account these potential changes without hindering the clear identification of the crystal form shown. A crystal form can be confirmed based on any unique combination of characteristic peaks.
[0097] Preparation 1
[0098] ( R )-1-chloro-3-(dibenzylamino)propan-2-ol
[0099]
[0100] Add dibenzylamine (200.0 g, 0.993 mol) and 2-propanol (200 mL) to the flask. Cool the solution to below 5°C with stirring using an ice / water bath. Add ( R )-(-)-epichlorohydrin (95 mL, 1.21 mol). The mixture was warmed to 21 °C and stirred for 2 days, then the resulting solution containing the title compound was refrigerated until used in the next step. ES-MS m / z 290 (M+H).
[0101] Preparation 2
[0102] ( R )-N,N-dibenzyl-1-(oxiran-2-yl)methylamine
[0103]
[0104] Method A: The ( R A solution of )-1-chloro-3-(dibenzylamino)propan-2-ol was poured into a flask with mechanical stirring and 2-propanol (466 mL) was used to complete the transfer. The solution was cooled to below 5°C with ice water, and then sodium hydroxide solution (5 mol / L in water, 240 mL, 1.18 mol) was added in 5 portions, and the mixture was then warmed to 20°C. After 6 hours, the mixture was transferred to a separatory funnel with toluene (500 mL) and water (100 mL). The mixture was shaken to separate the layers, and the bottom layer was removed. Water (250 mL) was added, the mixture was shaken and allowed to settle, and the bottom layer was removed. Saturated aqueous NaCl solution was added, the mixture was shaken and allowed to separate, and the bottom layer was removed. The solution was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The residue was dried in vacuo to produce the title compound as a slurry (270.7 g, 99% yield over 2 steps), which was obtained by 1 H-NMR indicated 8.7% w / w toluene. 1 H-NMR (400 MHz, CDCl3) δ 7.45-7.23 (m, 10H), 3.82(brd, J = 13.6 Hz, 2H), 3.59 (brd, J = 13.6 Hz, 2H), 3.10 (br, 1H), 2.79(brd, J = 12.8 Hz, 1H), 2.70 (t, J= 4.4 Hz, 1H), 2.48-2.40 (m, 2H). ES-MS m / z 254 (M+H).
[0105] Method B (by ( R )-(-)-epichlorohydrin) in one-pot procedure: Add dibenzylamine (152 kg, 770 mol) and 2-propanol (121 kg) to the container and stir the mixture at 10-20°C. Slowly add ( R )-(-)-epichlorohydrin (105 kg, 1135 mol) was added and the mixture was stirred at 10-20°C until the reaction reached <1% epichlorohydrin remaining. 20% w / w sodium hydroxide in water (183 kg, 915 mol NaOH) was slowly added and the mixture was stirred at 20-25°C. Another portion of 20% w / w sodium hydroxide in water (20 kg, 100 mol NaOH) was added and the mixture was stirred at 20-25°C until <0.5% intermediate remained. The layers were separated and the organic layer was concentrated under reduced pressure to approximately 200 L residual volume. EtOAc (688 kg) was added and the mixture was concentrated under reduced pressure to approximately 200 L residual volume, then EtOAc (683 kg) and water (460 kg) were added. The mixture was stirred, then settled and the aqueous layer was separated. Another portion of water (461 kg) was added to the organic layer. The mixture was stirred, then settled and the aqueous layer was separated. Another portion of water (451 kg) was added to the organic layer. The mixture was stirred, then settled and the aqueous layer was separated. The organic layer was concentrated under reduced pressure until about 130 L remained, and then tert-butyl alcohol (595 kg) was added. The mixture was concentrated under reduced pressure until about 130 L remained. The solution was diluted with tert-butyl alcohol (167 kg) to produce a solution of the title compound (373.4 kg solution, 50.8 wt%, 189.7 kg title compound, 749 mol, 97% yield). The HPLC retention time of the title compound was 14.0 min [HPLC: Waters XBridge C18 (4.6 × 150 mm, 3.5 µm), 35°C, 1.2 mL / min, detection at 215 nm, gradient: 5-95% B in 16 min, hold to 18 min, 5% B at 18.1 min; solvent A = 10 mM ammonium formate, pH 9.0, in purified water, solvent B = ACN].
[0106] Preparation 3
[0107] (S)-N,N-Dibenzyl-1-(oxetane-2-yl)methanamine
[0108]
[0109] Method A: The flask was equipped with mechanical stirring, nitrogen source, heating mantle, condenser and thermocouple. Trimethylsulfoxide iodide (66.5 g, 0.278 mol) was added to the flask, followed by solid potassium tert-butoxide (45.7 g, 0.371 mol) and tert-butanol (500 mL). The solution was stirred and heated to 85 °C and pressure transfer was added ( R )-N,N-dibenzyl-1-(oxiran-2-yl)methanamine (pure material from Preparation 2, Method A, 50.0 g, 0.186 mol) in tert-butanol (250 mL). The mixture was heated at 80-85°C (mild reflux) for 5 hours, then cooled and the solids removed by filtration. The solids were washed with hexanes (200 mL) and the hexanes wash filtrate was combined with the initial filtrate. The product solution was partially concentrated by rotary evaporation and transferred to a separatory funnel with hexanes (500 mL) and water (200 mL). The mixture was shaken, allowed to settle and the bottom layer was drained. Water (200 mL) was added, the mixture was shaken, allowed to settle and the bottom layer was drained; this was repeated two more times. The organic layer was washed with saturated aqueous NaCl solution and dried over sodium sulfate. The sodium sulfate was removed by filtration and the solution was concentrated to an oil by rotary evaporation. The oil was purified by silica gel chromatography using 15% EtOAc / hexanes to give the title compound as a yellow oil (23.4 g, 40%) which was purified by 1 H-NMR indicated ~85% purity. 1 H-NMR (400 MHz, CDCl3) δ 7.40-7.22 (m, 10H), 5.03 (brpent, J = 5.8 Hz, 1H), 4.63 (td, J = 6.1, 8.0 Hz, 1H), 4.46 (td, J = 5.9, 9.1 Hz,1H), 3.70 (brd, J = 13.7 Hz, 2H), 3.62 (brd, J = 13.7 Hz, 2H), 2.82 (dd, J =6.1, 13.5 Hz, 1H), 2.71 (dd, J = 4.5, 13.5 Hz, 1H), 2.56 (m, 1H), 2.36 (m, 1H). ES-MS m / z 268 (M+H).
[0110] To assess the optical purity of the title compound, prepare the title compound as a racemic mixture essentially as described in Preparations 1 to 3 starting from racemic epichlorohydrin.
[0111] The racemic mixture was analyzed by chiral HPLC (column: Chiralcel ® OD-H 4.6 × 150 mm; flow rate 1 mL / min; detection at 254 nm; eluent: 2:98 EtOH / heptane (v / v) + 0.1% DMEA). Using this method, the retention times of the respective enantiomers in the racemic sample were 7.48 min and 8.59 min. Analysis of the optically pure material showed 96% ee (1.8% at 7.49 min and 86.0% at 8.61 min by UV peak area).
[0112] Method B: Add trimethylsulfoxide iodide (250 kg, 1136 mol) to the container. Add potassium tert-butoxide (170.1 kg, 1516 mol) and tert-butanol (744 kg). Stir at 50-55°C for 2-3 hours, then at 65-75°C for 15-30 minutes, then heat to 75-80°C. Slowly add ( R )-N,N-dibenzyl-1-(oxiran-2-yl)methanamine in tert-butyl alcohol (from Preparation 2, Method B, 372.2 kg solution, 50.8 wt%, 189 kg, 749 mol). The mixture was heated to 80-90°C for 6-8 hours, then cooled to 30-40°C and EtOAc (534 kg) was added. The mixture was filtered and washed with EtOAc (51 + 54 + 60 + 59 + 59 + 60 + 60 + 60 kg). The mixture was concentrated under reduced pressure until about 200-400 L remained, then EtOAc (858 kg) was added and concentrated again under reduced pressure until about 200-400 L remained. EtOAc (861.5 kg) and water (570 kg) were added and the temperature of the mixture was adjusted to 20-30°C. Stirred, then the mixture was settled and the layers separated. Water (571 kg) was added, stirred, then the mixture was settled and the layers separated.
[0113] The organic layer was purified portion by portion. A portion of the organic layer was added to a container (176 kg) and concentrated under reduced pressure until approximately 32 L remained. A 4:1 v:v solution of heptane:EtOAc (25 kg), then silica gel (46 kg), then heptane (107 kg) was added to the mixture. The mixture was stirred at 20-30°C for 2-3 hours, then filtered and the silica gel was rinsed with three portions (~60 kg each) of a 10:1 w:w heptane:EtOAc solution containing 1.7 wt% triethylamine. The filter cakes were combined and concentrated under reduced pressure until approximately 20 L remained, then heptane (11 kg) was added. The heptane solution was chromatographed over a pad of silica gel (60 kg), eluting with a 10:1 w:w heptane:EtOAc mixture containing 1.7 wt% triethylamine, and the product-containing fractions were combined for further processing. The remaining portion of the organics was processed similarly and all chromatographed product fractions were combined.
[0114] The product fractions were concentrated under reduced pressure until about 200 L remained. EtOH (470 kg) was added to the mixture and concentrated under reduced pressure until about 200 L remained. The mixture was diluted with EtOH (297 kg) to produce a solution of the title compound (407.8 kg solution, 18.7 wt%, 76.3 kg title compound, 285 mol, 38% yield). The HPLC retention time of the title compound was 9.8 min [HPLC: Agilent Zorbax Bonus RP (4.6 × 150 mm, 3.5 µm), 35°C, 1.2 mL / min, 215 nm detection, gradient: 5-50% B in 15 min, reaching 95% B at 20 min, maintained until 22 min, 5% B at 22.1 min; solvent A = 0.05% TFA / purified water, solvent B = 0.05% TFA / ACN].
[0115] Preparation 4
[0116] ( S )-Oxetane-2-ylmethylamine hydrochloride
[0117]
[0118] In a pressure bottle, place ( S)-N,N-dibenzyl-1-(oxetan-2-yl)methanamine (pure material from Preparation 3, Method A, 46.0 g, 172 mmol) was dissolved in EtOH (460 mL) and aqueous HCl (5 M, 31 mL, 155 mmol) was added. Palladium on carbon (60 wt% water, 5% Pd loading on dry basis, 9.2 g) was added and the mixture was stirred at ambient temperature under 40 psig hydrogen for 20 hours. The mixture was purified by centrifugation through Celite ® The catalyst was removed by filtration and the solvent was removed by rotary evaporation.The residue was a colorless oil which crystallized upon standing to provide the title compound (20.8 g, 98%). 1 H-NMR (400 MHz, DMSO- d 6)δ 7.98 (br, 3H), 4.90 (m, 1H), 4.52 (ddd, J = 5.9, 7.2, 8.6 Hz, 1H), 4.46(td, J = 6.2, 9.0 Hz, 1H), 3.05 (dd, J = 6.4, 13.5 Hz, 1H), 2.98 (dd, J =4.3, 13.5 Hz, 1H), 2.66 (m, 1H), 2.52 (m, 1H).
[0119] Preparation 5
[0120] ( S )-Oxetane-2-ylmethylamine
[0121]
[0122] A solution of (S)-N,N-dibenzyl-1-(oxetan-2-yl)methanamine from Preparation 3, Method B in EtOH was added to the vessel (203.6 kg solution, 18.7 wt%, 38.1 kg starting material, 142 mol). Activated carbon (3.9 kg) was added to the solution and rinsed with EtOH (5 kg). The mixture was stirred for 4-6 hours, then filtered and rinsed with EtOH (38 + 39 +38 kg). The solution was concentrated to approximately 152 L remaining (187.6 kg solution, 19.9 wt%, 37.3 kg starting material, 140 mol). Acetic acid (10 kg) was then added and rinsed with EtOH (2 kg). Palladium on carbon (50 wt% water, 10 wt% Pd loading on dry basis, 1.87 kg) was added to the mixture and rinsed with EtOH (3 × 5 kg). The mixture was subjected to 0.3-0.5 MPa hydrogen pressure and heated to 40-50°C. After 5-6 hours, another portion of palladium on carbon (1.87 kg) was added to the reaction mixture and rinsed with EtOH (5 + 10 + 6 kg). The reaction mixture was subjected to 0.3-0.5 MPa hydrogen at 40-50°C. After 5-6 hours, another portion of palladium on carbon (1.87 kg) was added, rinsed with EtOH (10 + 10 + 11 kg), and the reaction mixture was subjected to 0.3-0.5 MPa hydrogen at 40-50°C. After 5-6 hours, another portion of palladium on carbon (1.87 kg) was added, rinsed with EtOH (10 + 5 + 6 kg), and the reaction mixture was subjected to 0.3-0.5 MPa hydrogen at 40-50°C. After 6-8 hours, another portion of palladium on carbon (0.38 kg) was added, rinsed with EtOH (6 + 7 + 5 kg), and the reaction mixture was subjected to 0.3-0.5 MPa of hydrogen at 40-50°C. After 5-6 hours, the reaction mixture was cooled to 15-25°C, filtered through celite (7 kg), and rinsed with EtOH (40 + 48 kg). The title compound was obtained as an EtOH solution (381 kg solution, 2.8 wt%, 10.75 kg of the title compound, 123 mol, 87% yield). The retention time of the title compound was 6.6 min [GC: DB-624, 30 m × 0.32 mm ID × 1.8 μm, FID detection at 280°C, make-up (N2) flow 30 mL / min, H2 flow 40 mL / min, air flow 400 mL / min, 60°C for 1 min, 30°C / min to 130°C, hold for 6 min, 30°C / min to 240°C, hold for 22 min. Injector temperature 240°C, 10:1 split ratio].
[0123] Preparation 6
[0124] ( S )-4-nitro-3-((oxetan-2-ylmethyl)amino)benzoic acid methyl ester
[0125]
[0126] Will( S )-Oxetane-2-ylmethylamine hydrochloride (20.8 g, 168 mmol) was dissolved in DMF (150 mL) and 3-fluoro-4-nitro-benzoic acid methyl ester (30.0 g, 151 mmol) was added, followed by triethylamine (45.7 g, 452 mmol). The mixture was stirred at ambient temperature for 20 hours. The mixture was poured into a separatory funnel and MTBE (400 mL) and water (400 mL) were added. The mixture was shaken, allowed to settle, and the bottom layer was removed. The organic layer was washed successively with water, saturated aqueous NaCl solution, and then dried over sodium sulfate. After filtration, the solution was concentrated by rotary evaporation and chromatographed on silica gel (1.5 kg) using EtOAc / isohexane (gradient elution, 0 to 40% (vol / vol) EtOAc to isohexane). The product-rich fractions were combined and concentrated by rotary evaporation to provide the product as a yellow solid (33.3 g, 125 mmol, 83% yield). Chiral HPLC analysis showed the product to have 94.2% ee (er = 97.1: 2.9).
[0127] Chiral HPLC conditions: 3:7 (v / v) EtOH / heptane containing 0.1% (w / w) DMEA, Chiralpak AD-H, 4.6 × 150 mm, 1 mL / min, 254 nm, S enantiomer = 7.93 min, R enantiomer = 9.50 min. 1H-NMR (400 MHz, CDCl3) δ 8.37 (br, 1H), 8.25 (d, J = 9.0 Hz, 1H), 7.64(d, J = 1.6 Hz, 1H), 7.28 (dd, J = 1.8, 8.8 Hz, 1H), 5.17 (m, 1H), 4.76 (ddd,J = 6.1, 7.6, 8.4 Hz, 1H), 4.64 (td, J = 6.0, 9.2 Hz, 1H), 3.95 (s, 3H), 3.64(t, J = 4.9 Hz, 2H), 2.79 (m, 1H), 2.62 (m, 1H). ES-MS m / z 267 (M+H).
[0128] Preparation 7
[0129] (S)-4-Nitro-3-((oxetan-2-ylmethyl)amino)benzoic acid
[0130]
[0131] Will( S )-oxetane-2-ylmethylamine (from Preparation 5, 6.9 kg assay correction, 79 mol) in EtOH was added to 3-fluoro-4-nitrobenzoic acid (15.3 kg, 83 moles, 1.05 equiv). Triethylamine (26 kg, 257 mol, 3.1 equiv) was added slowly, rinsed with EtOH (3 kg), and the mixture was heated to 110-120 °C in a sealed container until the remaining 3-fluoro-4-nitrobenzoic acid was <2%. The mixture was cooled, transferred to a bucket and rinsed with EtOH (15 kg). A total of 20.7 net kg of ( S)-oxetane-2-ylmethylamine (238 mol) and 45.6 kg 3-fluoro-4-nitrobenzoic acid (246 mol). The combined EtOH solution of the title compound was concentrated to about 100 L remaining, then EtOH (71 kg) was added and reconcentrated to about 100 L remaining. The mixture was cooled to 5-15°C and 15% w / w citric acid / water (287 kg) was slowly added. Stir for 1-2 hours, then filter the mixture and rinse with water (88 + 86 kg). The wet cake from the filtration was stirred in EtOH (113 kg) and the mixture was heated to 40-50°C. After 4-6 hours, the mixture was cooled to 5-15°C, stirred for 2-4 hours, then filtered and the cake was washed with EtOH (28 kg). The wet cake was dried to obtain the title compound as an orange solid (34.6 kg, 32.4 kg analytical correction, 137 moles, 58% yield). 1 H NMR (400 MHz, DMSO) δ 13.50 (s, 1H), 8.33 (t, J = 5.8 Hz, 1H), 8.16 (d, J = 8.9 Hz, 1H),7.66 (d, J = 1.7 Hz, 1H), 7.16 (dd, J = 8.9, 1.7 Hz, 1H), 5.00 (m, 1H), 4.60-4.38 (m, 2H), 3.74-3.58 (m, 2H), 2.71 -2.50 (m, 2H). The HPLC retention time of the title compound was 12.5 min [HPLC: Agilent Zorbax Bonus RP (4.6 × 150 mm, 3.5 μm), 35°C, 1.2 mL / min, 237 nm detection, gradient: 5-95% B in 20 min, 5% B at 20.1 min; solvent A = 0.05% TFA / purified water, solvent B = 0.05% TFA / ACN].
[0132] Preparation 8
[0133] (S)-4-Amino-3-((oxetan-2-ylmethyl)amino)benzoic acid
[0134]
[0135] (S)-4-nitro-3-((oxetane-2-ylmethyl)amino)benzoic acid (3.55 kg, 13.9 moles) and THF (35 L) were added to the container. Palladium on carbon (50 wt% water, 10 wt% Pd loading calculated on dry basis, 356 g) was added. Hydrogen pressure (0.3 Mpa) was applied to the reaction mixture at 35°C until the reaction was complete. ® The reaction mixture was filtered to remove the catalyst and then concentrated to about 7 L remaining. 17 L of EtOAc was added back and concentrated again to about 7 L remaining. Another 17 L of EtOAc was added back and concentrated to about 7 L remaining. Filtered and rinsed with EtOAc. The wet cake was dried under vacuum at 45-50 ° C to obtain the title compound as a brown solid (2.89 kg, 12.6 mol, 91% yield). The HPLC retention time of the title compound was 6.2 min [HPLC: Waters XBridge C18 (4.6 × 150 mm, 3.5 µm), 35 ° C, 1.2 mL / min, 237 nm detection, gradient: 5-95% B in 20 min, 5% B at 20.1 min; solvent A = 0.05% TFA / purified water, solvent B = 0.05% TFA / ACN].
[0136] Preparation 9
[0137] (S)-4-(2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-fluoro-5-methylphenyl)acetamido)-3-((oxetan-2-ylmethyl)amino)benzoic acid
[0138]
[0139] To a vessel was added 2-[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridinyl]-2-fluoro-5-methyl-phenyl]acetic acid (4.75 kg, 13.6 mol) (Preparations 9a to 9f below) and THF (25 kg). 1,1-Carbonyldiimidazole (2.6 kg, 17.7 mol, 1.3 eq.) was added and rinsed with THF (4 kg). The mixture was heated to 35-40°C for 0.5-1 hour, then (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoic acid (2.8 kg, 14.3 mol, 1.05 eq.) was added and rinsed with THF (4.2 kg). The mixture was stirred at 35-40°C until the reaction was complete, then cooled to 20-30°C and 5% citric acid / water (18.5 kg) was added. EtOAc (22 kg) was added, the mixture was stirred, then the layers were settled and separated. Another portion of 5% citric acid / water (18.5 kg) was added to the organic layer. Stir, then settle and separate the layers. Water (23.9 kg) was added to the organic layer. Stir, then settle and separate the layers. THF (32.8 + 26 kg) was added, followed by Si-Thiol scavenger (0.5 kg) and the mixture was stirred for 6-8 hours. The scavenger was filtered out and rinsed with THF (11 kg). The mixture was concentrated to about 10-15 L remaining, then EtOAc (21 kg) was added. This was repeated twice with two 20 kg portions of EtOAc. The mixture was concentrated again to about 10-15 L remaining, then EtOAc (20 kg) was added. The mixture was concentrated a third time to about 10-15 L remaining, then EtOAc (20 kg) was added. Filtered, then the wet cake was rinsed with EtOAc (13 kg). The wet cake was dried in vacuo at 30-40°C to obtain the title compound (4.35 kg, 8.2 mol, 60% yield) as an almost white solid. The HPLC retention time of the title compound was 16.0 min. [HPLC: Waters XBridge C18 (4.6× 150 mm, 3.5 µm), 35°C, 1.2 mL / min, 230 nm detection, gradient: 5-40% B in 7 min, reaching 95% B at 19 min, holding until 21 min, reaching 5% B at 21.1 min; solvent A = 0.05% TFA / purified water, solvent B = 0.05% TFA / ACN].
[0140] 2-[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridinyl]-2-fluoro-5-methyl-phenyl]acetic acid, one of the raw materials in the above preparation 9, can be prepared according to the following preparation method:
[0141] Preparation 9a
[0142] (4-Bromo-2-fluoro-5-methylphenyl)methanol
[0143]
[0144] To a flask was added: 4-bromo-2-fluoro-5-methylbenzoic acid (100 g, 421 mmol), THF (200 mL) and borane (dimethyl sulfide complex, 2 mol / L solution in THF, 210 mL, 10 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was quenched with HCl (1.0 N aqueous solution, 50 mL) and the mixture was filtered. The filtrate was concentrated in vacuo and the residue was partitioned between EtOAc (400 mL) and water (400 mL). The organics were washed with saturated aqueous NaCl solution (400 mL), dried over Na2SO4, filtered and concentrated to yield the title compound (93.5 g, 99%) as a solid. 1 H-NMR (400MHz, CDCl3) δ 7.29 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 9.1 Hz, 1H), 4.69 (s, 2H), 2.38 (s, 3H).
[0145] Preparation 9b
[0146] 2-(4-Bromo-2-fluoro-5-methylphenyl)acetonitrile
[0147]
[0148] (4-Bromo-2-fluoro-5-methylphenyl)methanol (92 g, 420 mmol) was dissolved in DCM (500 mL) and triethylamine (120 mL, 861 mmol) was added. The mixture was cooled to -15 °C and a solution of methanesulfonyl chloride (40 mL, 517 mmol) in DCM (30 mL) was added dropwise to the reaction mixture. The mixture was stirred at room temperature for 30 minutes. The reaction mixture was partitioned between DCM (500 mL) and water (500 mL). The organics were washed with saturated aqueous NaCl solution (500 mL), dried over Na2SO4, filtered and concentrated. The residue was dissolved in DMF (400 mL) and the mixture was cooled with an ice bath. NaCN (21.0 g, 429 mmol) was added to the reaction mixture in one portion and stirred at room temperature overnight. The mixture was partitioned between EtOAc (400 mL) and water (500 mL). The organics were washed with saturated aqueous NaCl solution (500 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography using a 10 to 30% EtOAc / hexane gradient to produce the title compound (47.0 g, 48%) as an oil. 1H-NMR (400 MHz, CDCl3) δ 7.34 (d, J = 8.7 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 3.71 (s, 2H), 2.41 (s, 3H).
[0149] Preparation 9c
[0150] 2-(4-Bromo-2-fluoro-5-methyl-phenyl)acetic acid methyl ester
[0151]
[0152] To a flask was added: 2-(4-bromo-2-fluoro-5-methylphenyl)acetonitrile (1.20 g, 5.10 mmol), EtOH (5 mL), water (3 mL), and potassium hydroxide (0.90 g, 16 mmol). The mixture was heated at 90 °C overnight. The mixture was cooled with an ice bath and acidified to pH 4-5 with 1.0 M HCl, then the mixture was partitioned between EtOAc (30 mL) and water (30 mL). The organics were washed with saturated aqueous NaCl solution (30 mL), dried over Na2SO4, filtered, and concentrated to yield 2-(4-bromo-2-fluoro-5-methyl-phenyl)acetic acid as a solid. This was dissolved in DCM (10 mL), then DMF (0.05 mL, 0.6 mmol) and oxalyl chloride (0.5 mL, 6 mmol) were added at room temperature. The mixture was stirred at room temperature for 30 minutes, then MeOH (2 mL, 49.4 mmol) was added dropwise. After 30 minutes, the solvent was removed in vacuo and the residue was partitioned between EtOAc (40 mL) and 5% NaHCO3 (30 mL). The organics were washed with saturated aqueous NaCl (40 mL), dried over Na2SO4, filtered and concentrated to give the title compound as an oil (1.1 g, 80%). ES / MS m / z ( 79 Br, 81 Br) 278,280 (M+NH4 + ).
[0153] Preparation 9d
[0154] 2-[2-Fluoro-4-(6-hydroxy-2-pyridinyl)-5-methyl-phenyl]acetic acid methyl ester
[0155]
[0156] To a flask was added 6-hydroxypyridine-2-boronic acid pinacol ester (1.6 g, 6.9 mmol), methyl 2-(4-bromo-2-fluoro-5-methyl-phenyl)acetate (2.2 g, 8.4 mmol), THF (15 mL), water (1 mL), and potassium carbonate (2.0 g, 14 mmol). The mixture was purged with nitrogen for 10 minutes, then Pd(dppf)Cl2 (0.26 g, 0.35 mmol) was added and heated at 75 °C for 2 hours. The mixture was partitioned between EtOAc (30 mL) and water (30 mL). The organics were washed with saturated aqueous NaCl solution (30 mL), dried over Na2SO4, filtered and concentrated to give the title compound as a solid (1.4 g, 74%). ES / MS m / z276 (M+H), 274 (MH).
[0157] Preparation 9e
[0158] 2-[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridinyl]-2-fluoro-5-methyl-phenyl]acetic acid methyl ester
[0159]
[0160] To a flask was added methyl 2-[2-fluoro-4-(6-hydroxy-2-pyridinyl)-5-methyl-phenyl]acetate (1.40 g, 5.09 mmol), 1,4-dioxane (35 mL), silver carbonate (1.7 g, 6.2 mmol) and 4-(bromomethyl)-3-fluorobenzonitrile (1.4 g, 6.2 mmol). The mixture was heated at 60 °C overnight. The solid was filtered off and the filtrate was concentrated. The residue was purified by silica gel chromatography using 12 to 55% EtOAc / hexanes to produce the title compound (1.60 g, 77%) as a solid. ES / MS m / z 409 (M+H), 407 (MH).
[0161] Preparation of 9f
[0162] 2-[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridinyl]-2-fluoro-5-methyl-phenyl]acetic acid
[0163]
[0164] To a vial was added methyl 2-[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridinyl]-2-fluoro-5-methyl-phenyl]acetate (1.6 g, 3.9 mmol), ACN (20 mL), water (6 mL) and lithium hydroxide (0.45 g, 19 mmol). The mixture was heated at 45 °C for 2 hours, cooled with an ice bath and acidified to pH = 4-5 with 1.0 M HCl. The mixture was partitioned between EtOAc (50 mL) and water (50 mL). The organics were washed with saturated aqueous NaCl solution (50 mL), dried over Na2SO4, filtered and concentrated to give the title compound as a solid (1.55 g, 100%). ES / MS m / z 395 (M+H).
[0165] Preparation 10
[0166] 2-[[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridinyl]-2-fluoro-5-methyl-phenyl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid tert-butylammonium
[0167]
[0168] (S)-4-(2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-fluoro-5-methylphenyl)acetamido)-3-((oxetan-2-ylmethyl)amino)benzoic acid (2.05 kg, 3.4 moles) and THF (19 kg) were combined and the mixture was heated to 115-125°C in a sealed container until the reaction was complete and then rinsed into a drum with THF (7 kg). This reaction was combined with another reaction run in a similar manner at a 2.05 kg scale. The product solution was recirculated through an activated carbon cartridge filter for 6-8 hours and then the filter was rinsed with THF (7.8 kg). This solution was recirculated through a fresh activated carbon cartridge filter for 4-6 hours and then the filter was rinsed with THF (8.4 kg). The solution was concentrated to 8-12 L remaining and then acetone (17 kg) was added. The solution was further concentrated to 8-12 L remaining and then acetone (18 kg) was added. The solution was concentrated for the third time to 8-12 L remaining, and acetone (38 kg) was added. The mixture was heated to 45-55 ° C and purified water (1.7 kg) was added. A solution of 2-methyl-2-propylamine (0.7 kg, 9.6 mol, 1.4 equivalents) in acetone (3.4 kg) was prepared. 1 / 5 of the 2-methyl-2-propylamine solution was added to the product solution. Seed crystals of the title compound (18.57 g) were added and the mixture was stirred for 1-2 hours, and then the remaining 2-methyl-2-propylamine solution was slowly added. The mixture was stirred for 1-2 hours and then slowly cooled to 15-20 ° C. The solid was filtered out and rinsed with acetone (10 kg). The solid was dried in a vacuum at 45-55 ° C to obtain the title compound (3.48 kg, 5.1 mol, 75% yield) as a white solid. The HPLC retention time of the title compound is 14.8 min. [HPLC: Waters XBridge C18 (4.6 × 150 mm, 3.5 µm), 35°C, 1.2 mL / min, detection at 220 nm, gradient: 5-40% B in 6 min, 95% B at 28 min, 5% B at 28.1 min; solvent A = 0.05% TFA / purified water, solvent B = 0.05% TFA / ACN].
[0169] The prepared sample of the title compound was characterized by an XRD pattern using CuKα radiation as having diffraction peaks (2-θ values) as described in Table 1 below, specifically having a peak at 6.9 and one or more peaks selected from 16.3 and 22.5; the tolerance of the diffraction angle was 0.2 degrees.
[0170] Table 1. X-ray powder diffraction peaks of tert-butylammonium 2-[[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridinyl]-2-fluoro-5-methyl-phenyl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate
[0171] peak Angle (°2-θ) + / - 0.2° Relative intensity (% of the strongest peak) 1 5.5 26.20% 2 6.9 64.90% 3 11.2 49.20% 4 16.3 100.00% 5 17.1 34.70% 6 19.6 53.00% 7 21.8 43.10% 8 22.5 93.80% 9 27.3 41.10% 10 28.0 37.90%
Claims
1. A method for preparing a compound of the following formula or a salt thereof: It includes the following steps: i. Combining dibenzylamine and a compound of the formula: A base is then added to produce a compound of the formula: ii. taking trimethyl sulfoxide halide in the presence of a base and combining with the solution of the compound obtained from step (i) and heating to above 40°C to produce a compound of the formula: iii. deprotecting the compound obtained in step (ii), The base in step (ii) is selected from potassium tert-butoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-amylate, lithium tert-amylate, sodium tert-amylate, lithium potassium hydride, sodium hydride, potassium hydride, n-butyllithium in an alcohol solvent, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide or potassium bis(trimethylsilyl)amide.
2. The method according to claim 1, wherein the compound prepared is a compound of the formula: or a salt thereof.
3. A method according to claim 1 or claim 2, wherein the trimethyl sulfoxide halide is trimethyl sulfoxide iodide.
4. The process according to claim 1, wherein the base in step (ii) is potassium tert-butoxide.
5. The method according to claim 1 or 2, wherein the solution in step (ii) comprises a solvent selected from tert-butyl alcohol, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or tert-amyl alcohol.
6. The process according to claim 5, wherein the solvent is tert-butyl alcohol.
7. The process according to claim 1 or 2, wherein step (ii) is carried out at a temperature above 70°C.
8. The process according to claim 1 or 2, wherein step (iii) is carried out using a palladium catalyst.
9. The process according to claim 8, wherein the palladium catalyst is palladium on carbon.
10. The method according to claim 1 or 2, further comprising the steps of: A base and a compound of the formula: Wherein R is H or an acid protecting group, Combined with a solution of a compound of the formula: To produce the following compound:
11. The method according to claim 10, wherein R is H or C 1-4 alkyl.
12. The method according to claim 10, further comprising the steps of: Reduction of the nitro group of the compound of the formula: To produce the compound of the formula:
13. The method according to claim 12, further comprising the steps of: a. Carry out with the compound of the following formula: With the amide coupling reaction of the compound of the following formula: To produce the following compound: or its salts; b. subjecting the compound obtained from step (a) to a cyclization reaction to produce a compound of the formula: and optionally reacting to form a pharmaceutically acceptable salt thereof.
14. The method according to claim 13, wherein R is an acid protecting group, and the method further comprises the following steps: The ester group is hydrolyzed to produce the acid compound of the formula: and optionally reacting to form a pharmaceutically acceptable salt thereof.
15. A method according to claim 13 or claim 14, wherein the compound prepared is the tert-butylamine salt of the compound of the formula:
16. Compounds of the formula: or a salt thereof.
17. A compound according to claim 16, which is: or a salt thereof.
18. Use of a compound according to claim 16 or 17 in the preparation of a compound of the following formula or a pharmaceutically acceptable salt thereof:
Citation Information
Cited By
Synthesis method of (S)-oxetane-2-methylamine and intermediate of (S)-oxetane-2-methylamine
CN120058644A
